Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Dana L. Schalk"'
Autor:
Jeffrey M. Sturek, Tania A. Thomas, James D. Gorham, Chelsea A. Sheppard, Allison H. Raymond, Kristen Petros De Guex, William B. Harrington, Andrew J. Barros, Gregory R. Madden, Yosra M. Alkabab, David Y. Lu, Qin Liu, Melinda D. Poulter, Amy J. Mathers, Archana Thakur, Dana L. Schalk, Ewa M. Kubicka, Lawrence G. Lum, Scott K. Heysell
Publikováno v:
Microbiology Spectrum, Vol 10, Iss 1 (2022)
ABSTRACT The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an unprecedented event requiring frequent adaptation to changing clinical circumstances. Convalescent immune plasma (CIP) is a promising trea
Externí odkaz:
https://doaj.org/article/9c79a21b9c364848a5066e1655b6206b
Autor:
Archana Thakur, John Scholler, Ewa Kubicka, Edwin T. Bliemeister, Dana L. Schalk, Carl H. June, Lawrence G. Lum
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Adoptive T cell therapies for solid tumors is challenging. We generated metabolically enhanced co-activated-T cells by transducing intracellular co-stimulatory (41BB, ICOS or ICOS-27) and CD3ζ T cell receptor signaling domains followed by arming wit
Externí odkaz:
https://doaj.org/article/44fc3950d1424b9fb6857b674cd72b67
Autor:
Archana Thakur, Johnson Ung, Elyse N. Tomaszewski, Amy Schienschang, Timothy M. LaBrie, Dana L. Schalk, Lawrence G. Lum
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
In this study, we investigated the ability of bispecific antibody armed activated T cells to target drug resistant pancreatic cancer cells and whether or not “priming” these resistant cancer cells with bispecific antibody armed activated T cells
Externí odkaz:
https://doaj.org/article/3062abc026db4ed09e0ef23859a8ffd7
Autor:
John Scholler, Dana L Schalk, Lawrence G. Lum, Archana Thakur, Edwin T. Bliemeister, Ewa Kubicka, Carl H. June
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
Adoptive T cell therapies for solid tumors is challenging. We generated metabolically enhanced co-activated-T cells by transducing intracellular co-stimulatory (41BB, ICOS or ICOS-27) and CD3ζ T cell receptor signaling domains followed by arming wit
Autor:
Dana L Schalk, Archana Thakur, Timothy M LaBrie, Johnson Ung, Lawrence G. Lum, Amy Schienschang, Elyse N. Tomaszewski
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
In this study, we investigated the ability of bispecific antibody armed activated T cells to target drug resistant pancreatic cancer cells and whether or not “priming” these resistant cancer cells with bispecific antibody armed activated T cells
Autor:
Melissa Giroux, Vidya Kondadasula, Archana Thakur, Dana L Schalk, Zaid S. Al-Kadhimi, Kristie Fields, Patricia A. Steele, Abhinav Deol, Elyse Tomashewski, Lawrence E. Flaherty, Lawrence G. Lum, Qin Liu, Michael S. Simon
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundMetastatic human epidermal growth receptor II (HER2) negative breast cancer remains incurable. Our phase I study showed that anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) may be effective against HER2-tumors.
Publikováno v:
J Cancer Res Clin Oncol
PURPOSE: Although adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells has shown durable clinical efficacy in patients with CD19(+) B-cell malignancies, the application of this approach to solid tumors is challenging. The goa
Autor:
Sri Vidya Kondadasula, Archana Thakur, Kyungmin Ji, Amro Aboukameel, Bonnie F. Sloane, Dana L Schalk, Eli V. Casarez, Johnson Ung, Edwin T. Bliemeister, Lawrence G. Lum
Publikováno v:
Cancer Immunol Immunother
Adoptive transfer of Bispecific antibody Armed activated T cells (BATs) showed promising anti-tumor activity in clinical trials in solid tumors. The cytotoxic activity of BATs occurs upon engagement with tumor cells via the bispecific antibody (BiAb)
Autor:
Dana L Schalk, Melissa Dufrense, Vidya Kondadasula, Archana Thakur, Philip A. Philip, Minsig Choi, Abhinav Deol, Hussein D Aon, Anthony F. Shields, Lawrence G. Lum, Gregory Dyson, Kristie Fields
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Oncoimmunology
article-version (VoR) Version of Record
Oncoimmunology
article-version (VoR) Version of Record
Purpose This was a phase I/II adoptive T cell trial in 7 locally advanced and metastatic pancreatic cancer patients using 3–8 infusions of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATs) to determine safety, the maximum tole
Autor:
Dana L Schalk, Tracey J Guerin-Edbauer, Manohar Ratnam, Cecilia L. Speyer, David H. Gorski, Lauren E Leakan, Eric D Frontera, Rafa M. Khansa
Publikováno v:
Breast Cancer Research and Treatment. 172:551-560
PURPOSE: According to the American Cancer Society, 1 in 8 women in the U.S. will develop breast cancer, with triple negative breast cancer (TNBC) comprising 15-20% of all breast cancer cases. TNBC is an aggressive subtype due to its high metastatic p